This is a randomized, placebo controlled, four period incomplete block,crossover thorough QT
study to estimate the effect of repeat dose GSK573719/GW642444M (Vilanterol) combination and
GSK573719 monotherapy on the QTc interval in healthy male and female subjects compared with
placebo. At least 100 subjects will receive, four of five possible, 10-day repeat dose
treatments. Treatments are placebo with a moxifloxacin placebo on day 10, placebo with
moxifloxacin (400mg) on day 10, GSK573719/Vilanterol combination (125/25μg) with moxifloxacin
placebo on day 10, GSK573719/Vilanterol combinatio (500/100μg) with moxifloxacin placebo on
day 10, or GSK573719 (500μg) with a moxifloxacin placebo on day 10. All treatments are double
blind except for moxifloxacin (400mg) and moxifloxacin placebo controls, given as a
single-blind single dose on Day 10 of the appropriate treatment period.
Primary endpoints are individual time-matched changes from baseline QTcF for
GSK573719/Vilanterol combination (125/25μg) and GSK573719 (500μg), 0-24 hours after dosing on
Day 10. Secondary endpoints will include individual time-matched changes from baseline in
QTcF for GSK573719/Vilanterol combination (500/100μg) and moxifloxacin (400mcg) 0-24 hours
after dosing on Day 10. Also changes from baseline in QTci, QTcB, QT, QRS, RR, PR and
ventricular rate at each time point after 10 days dosing of each GSK573719 and
GSK573719/Vilanterol treatment and single dose moxifloxacin (400mg). Maximal change from
baseline 0-24hours after dosing on day 10 will be derived for QTcF, QTci and QTcB for each
treatment. Plasma concentrations on Day 10 (0-24 hours) and pharmacokinetic parameters of
GSK573719 and Vilanterol will also be derived. Key assessments: 12- lead electrocardiogram
(ECG), pharmacokinetics. Safety will be assessed by blood pressure, heart rate, clinical
laboratory safety tests and collection of adverse events (AEs).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination